Figure 2

a

Expression (normalized)

<table>
<thead>
<tr>
<th>Clonotype</th>
<th>4-1BB</th>
<th>CD8</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;1</td>
<td>0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>&gt;2</td>
<td>44.8</td>
<td>54.1</td>
</tr>
<tr>
<td>&gt;3</td>
<td>45.3</td>
<td>52.8</td>
</tr>
<tr>
<td>&gt;4</td>
<td>1.2</td>
<td>4.4</td>
</tr>
</tbody>
</table>

Percent

<table>
<thead>
<tr>
<th>Clonotype</th>
<th>PBMC</th>
<th>NSCLC TIL</th>
<th>Lung N-TIL</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;1</td>
<td>56</td>
<td>75</td>
<td>25</td>
</tr>
<tr>
<td>&gt;2</td>
<td>50</td>
<td>75</td>
<td>50</td>
</tr>
<tr>
<td>&gt;3</td>
<td>75</td>
<td>75</td>
<td>50</td>
</tr>
<tr>
<td>&gt;4</td>
<td>75</td>
<td>75</td>
<td>75</td>
</tr>
</tbody>
</table>

Log(P value)

<table>
<thead>
<tr>
<th>Pathway</th>
<th>2.5</th>
<th>5.0</th>
<th>7.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell cycle: G2/M DNA damage checkpoint regulation (8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Role of CHK proteins in cell cycle checkpoint control (6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hereditary breast cancer signaling (14)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Role of BRCA1 in DNA damage response (10)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PS3 signaling (9)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

b

Cell cycle: G2/M DNA damage checkpoint regulation (8)

Mitotic roles of Polo-Like Kinase (9)

ATM signaling (13)

Role of BRCA1 in DNA damage response (10)

PS3 signaling (9)

Chromosome 16

PLK1

Chromosome 5

CCNB1

Chromosome 12

CD27

Chromosome 1

JUN

RNA Expression (RPKM)

Number of clonotypes

Percent

Log(P value)

Cell cycle: G2/M DNA damage checkpoint regulation (8)

Role of CHK proteins in cell cycle checkpoint control (6)

Hereditary breast cancer signaling (14)

Role of BRCA1 in DNA damage response (10)

PS3 signaling (9)

Chromosome 16

PLK1

Chromosome 5

CCNB1

Chromosome 12

CD27

Chromosome 1

JUN

Gene expression

Pathway

Number of clonotypes

Percent

Log(P value)